Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells. - Wikidata - wikimedia - TriplyDB

Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells.

Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells.

http://www.wikidata.org/entity/Q39730373

about

The mTOR pathway in obesity driven gastrointestinal cancers: Potential targets and clinical trials Role of Akt signaling in resistance to DNA-targeted therapy Chemoresistance and targeted therapies in ovarian and endometrial cancers The role of proline rich tyrosine kinase 2 (Pyk2) on cisplatin resistance in hepatocellular carcinoma Identification of an annonaceous acetogenin mimetic, AA005, as an AMPK activator and autophagy inducer in colon cancer cells Long Noncoding RNA GAS5, Which Acts as a Tumor Suppressor via microRNA 21, Regulates Cisplatin Resistance Expression in Cervical Cancer.ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer.Proteomic analysis identified DJ-1 as a cisplatin resistant marker in non-small cell lung cancer.Comparison of Intracellular Stress Response of NCI-H526 Small Cell Lung Cancer (SCLC) Cells to Platinum(II) Cisplatin and Platinum(IV) Oxoplatin.Inhibition of PI3K/Akt/mTOR signaling pathway enhances the sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin in vitro.The mTORC2 component rictor contributes to cisplatin resistance in human ovarian cancer cells.Variation in cell signaling protein expression may introduce sampling bias in primary epithelial ovarian cancer Bim protein degradation contributes to cisplatin resistance.BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival.RNA silencing of integrin-linked kinase increases the sensitivity of the A549 lung cancer cell line to cisplatin and promotes its apoptosis.Suppression of MAPK Signaling and Reversal of mTOR-Dependent MDR1-Associated Multidrug Resistance by 21α-Methylmelianodiol in Lung Cancer Cells Contributions of the Epidermal Growth Factor Receptor to Acquisition of Platinum Resistance in Ovarian Cancer Cells.S-Nitrosoglutathione-mediated STAT3 regulation in efficacy of radiotherapy and cisplatin therapy in head and neck squamous cell carcinoma.Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study.Vascular endothelial growth factor A as predictive marker for mTOR inhibition in relapsing high-grade serous ovarian cancer The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer.MiR-218 impairs tumor growth and increases chemo-sensitivity to cisplatin in cervical cancer AKT inhibition mitigates GRP78 (glucose-regulated protein) expression and contribution to chemoresistance in endometrial cancers.Blockade of PI3K/AKT pathway enhances sensitivity of Raji cells to chemotherapy through down-regulation of HSP70 Oncogenic NanogP8 expression regulates cell proliferation and migration through the Akt/mTOR signaling pathway in human gastric cancer - SGC-7901cell line microRNA-199a is able to reverse cisplatin resistance in human ovarian cancer cells through the inhibition of mammalian target of rapamycin.Human C1q Induces Apoptosis in an Ovarian Cancer Cell Line via Tumor Necrosis Factor Pathway.Urokinase-type plasminogen activator receptor promotes proliferation and invasion with reduced cisplatin sensitivity in malignant mesothelioma.The involvement of Bcl-2 family proteins in AKT-regulated cell survival in cisplatin resistant epithelial ovarian cancer.The role of microRNA in the response to cisplatin treatment.Non-invasive imaging of PI3K/Akt/mTOR signalling in cancer.Investigational therapies currently in Phase II clinical trials for the treatment of pelvic serous carcinomas.6-Gingerol Mediates its Anti Tumor Activities in Human Oral and Cervical Cancer Cell Lines through Apoptosis and Cell Cycle Arrest.CCR9-CCL25 interaction suppresses apoptosis of lung cancer cells by activating the PI3K/Akt pathway.The Akt inhibitor MK-2206 enhances the cytotoxicity of paclitaxel (Taxol) and cisplatin in ovarian cancer cells.Strategic targeting of the PI3K-NFκB axis in cisplatin-resistant NSCLC.Drug resistance and cancer stem cells: the shared but distinct roles of hypoxia-inducible factors HIF1α and HIF2α.Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation.Gambogic acid promotes apoptosis and resistance to metastatic potential in MDA-MB-231 human breast carcinoma cells.Alterations of phosphoproteins in NCI-H526 small cell lung cancer cells involved in cytotoxicity of cisplatin and titanocene Y.

P2860

Q26751155-8299E633-19B5-4B91-8256-F39667F3A65B Q28066950-4A7E0566-9883-4FCC-9DF4-CC8BB15B1819 Q28073246-77CF8A2F-A2E3-41D7-B45C-38F20F646245 Q28477884-948B09B7-7C6D-47AE-B69F-0E6EE6B8F581 Q28484273-496813A3-19E0-4480-8383-3505A5A76E3C Q30491599-3A06FDC4-3759-46B5-8C75-B4BDBD5D6AED Q33648465-1AF9EA3E-326A-48FF-A106-B6CB459DE382 Q33957809-C97D7336-9027-4E6D-8C3B-DD7E340D6725 Q34309915-8D65DAD6-F809-40E6-87B7-FAFEEB40CCAF Q34452761-78795B2F-A692-4A09-A7B9-D12E770A3841 Q35005636-A6AB5881-8AD3-45EA-A452-0B2E6EA6EED6 Q35035679-0B741523-D60B-4469-A4BC-76C63772AE4F Q35063113-6D3B1211-3CA6-4549-AAD2-80235906088A Q35269409-27AD8D6D-9270-47E9-9FEB-11B8FBC2F96C Q35628583-93C9972F-BE10-4025-9320-27D871B82F6B Q35670917-268FDB40-861E-4FB9-89CF-F73D7863DC89 Q35767493-3A50A7C1-43C8-4DDC-AE22-2226D81B62B8 Q35880215-49703B73-D663-42EF-A838-29A1292A93CB Q35932794-B7A1C66B-D57F-4205-9666-6950E6CDE8A0 Q35992948-3AE003DF-E0F6-48A8-AE65-B3EA9E5CE041 Q36242802-05D6A6E4-21D4-49EE-AA26-335CDAFE45AF Q36538354-61E1C88B-C890-4A53-83A2-E11AE5702544 Q36788196-AD190416-E35F-436A-801C-07D381B80051 Q36922834-965CFD05-AD24-425D-8B3F-913521C06DF6 Q37174814-DED9A494-6055-4D61-AB85-807D09C94CC0 Q37211707-5104CBE3-7233-4C37-ABE0-23E1BC7EEB9F Q37521362-8CE3C3B4-3415-4CD3-A5DD-EDFE4DB4FB08 Q37688399-834E9EAC-2C93-40F6-B11E-E1B316F5583B Q37702100-FB4BCB96-6B41-4F7B-961D-8834547643D7 Q38027966-1F284C43-0ED8-4539-BF71-F4703669CF4C Q38059212-D1E5C8DF-3E81-44FA-88E8-54F305ACD788 Q38340008-5BE39D12-3827-4B97-B2CC-232C2B7C8C87 Q38805200-E9CC4E8D-4FBF-42C6-AEB8-F2D0B1B96A53 Q38908550-5495D06B-E61E-4B7B-A663-4703C47A0782 Q38962245-2D728B40-71D6-4851-A253-5DF1D2ABD992 Q38975225-D414B5A6-CDB6-4D98-B1C3-F93303453E62 Q38997399-719E6FA7-AD81-4AFC-A167-8560FA23C5C1 Q39213121-28FF7E1F-2F47-474E-AD64-66DF4956F1B3 Q39235972-0DD32174-97C1-465D-B73B-D5D0139F6396 Q39270001-38F0018C-9811-48E1-B2FB-9395B926D42C

P2860

Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells.

http://www.wikidata.org/entity/Q39730373

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells.

@en

Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells.

@nl

type

label

Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells.

@en

Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells.

@nl

prefLabel

Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells.

@en

Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells.

@nl

P1433

Q39730373-CBCFFE8C-380E-403D-9E18-108EB64025F4

P1476

Q39730373-D5ACC99A-B724-448B-AEC6-59543D898694

P2093

Q39730373-114A09E7-7D52-4F8F-8FB2-0BCA8867C1F3

Q39730373-D0A05C90-223D-427F-BEAA-EE883A0ADD38

Q39730373-E71D8EE7-F475-498F-BA5B-BA8D66F8508A

Q39730373-ED8AF021-DBB7-43BD-90A4-3FCB08066D5D

P2860

Q39730373-069FFA08-7207-4C14-AABD-F524E00D2B48

Q39730373-083B8EA8-1859-4A47-94E3-60B336850EFC

Q39730373-19ECF319-2E7A-43F5-9039-F81C43354B10

Q39730373-23304CA8-5F1F-4DC4-A096-B217B8426B5E

Q39730373-2D30AE07-8F6A-488B-BE06-E33117D64164

Q39730373-36382221-8240-411E-B625-D72CDF6E5E7E

Q39730373-4B0CCA91-1461-4903-BA34-2F5820FB4F3D

Q39730373-52B14A5E-2F79-4446-A6B4-C9B16E00E5EA

Q39730373-59927F07-07B6-4227-9714-91090D2C3E51

Q39730373-59A7BBAC-4A57-4DCE-92DA-8B5BF13D5CDF

P304

Q39730373-464FBA90-7162-4163-8F06-99CAB985ECC4

P31

Q39730373-57C82A14-8259-4AC0-A7C0-0050B3A0B8BF

P356

Q39730373-1EAC4244-1BA5-4258-9284-39043426E661

P407

Q39730373-0FBE9854-63BF-42F0-AD92-D0692EFF66F8

P433

Q39730373-12763621-E6F4-4DFC-9907-EBEAC3C28801

P478

Q39730373-078C3259-D053-4791-BC7A-7A2117ECBE35

P577

Q39730373-EE2D2765-26B7-4A0D-9BEC-F98318147663

P698

Q39730373-605290D3-6E59-4549-AFB6-8A6E33AF4D7A

P921

Q39730373-1B3E9893-215A-481F-833D-67CDA029E6E8

P932

Q39730373-67CB9DC9-26F4-4943-9CCC-8AD6919B852E

P356

J.BBRC.2010.03.029

P1433

Biochemical and Biophysical Research Communications

P1476

Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells.

@en

P2093

Dong-Jun Peng

http://www.w3.org/2001/XMLSchema#string

Gen Sheng Wu

http://www.w3.org/2001/XMLSchema#string

Juan Wang

http://www.w3.org/2001/XMLSchema#string

Jun-Ying Zhou

http://www.w3.org/2001/XMLSchema#string

P2860

Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin.

Involvement of MKP-1 and Bcl-2 in acquired cisplatin resistance in ovarian cancer cells.

Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy.

Nitric oxide and cisplatin resistance: NO easy answers.

The resurgence of platinum-based cancer chemotherapy.

Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer.

Ovarian cancer: strategies for overcoming resistance to chemotherapy.

The Akt-mTOR tango and its relevance to cancer.

BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma

Cisplatin sensitizes cancer cells to ionizing radiation via inhibition of nonhomologous end joining.

P304

600-605

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BBRC.2010.03.029

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

394

http://www.w3.org/2001/XMLSchema#string

P577

2010-03-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20214883

http://www.w3.org/2001/XMLSchema#string

P921

P932

4063277

http://www.w3.org/2001/XMLSchema#string